Ten patent-pending programs

Novel de novo-designed cyclic peptides targeting an undisclosed cell-surface antigen broadly expressed in prostate adenocarcinoma, developed as radioligand therapy for castration-resistant disease beyond today’s approved radioligands.

Novel de novo-designed cyclic peptides targeting an undisclosed receptor expressed in prostate and ER+ breast cancers, developed as radioligand therapy vectors.

Novel de novo-designed cyclic peptide ligands of an undisclosed receptor for radioligand therapy in endometrial carcinoma and other target-expressing cancers.

Novel de novo-designed cyclic peptides targeting an undisclosed, clinically-validated tumor antigen in multiple myeloma, held as non-radiation composition IP for peptide-drug-conjugate, payload, and bispecific formats.

Novel de novo-designed cyclic peptides targeting an undisclosed orphan GPCR over-expressed in colorectal and urothelial tumors, held as non-radiation composition IP for peptide-drug-conjugate, payload, and bispecific formats.

Novel de novo-designed cyclic peptide antagonists of an undisclosed, validated CNS receptor linked to neurological and psychiatric disorders.

Novel de novo-designed cyclic peptide modulators of an undisclosed CNS receptor — antagonists for depression and anxiety, and Gq-biased agonists for developmental epileptic encephalopathy (DEE) and obesity.

Novel de novo-designed cyclic peptide agonists of an undisclosed, validated cardiovascular GPCR, targeting heart failure with reduced ejection fraction (HFrEF), pulmonary arterial hypertension (PAH), and related cardiometabolic indications.

Novel de novo-designed cyclic peptides targeting an undisclosed class B GPCR, explored for obesity and metabolic indications.

Novel de novo-designed cyclic peptide positive allosteric modulators (calcimimetics) of an undisclosed, clinically-validated receptor, targeting secondary hyperparathyroidism in chronic kidney disease–mineral and bone disorder (CKD-MBD). The calcimimetic mechanism is validated by approved therapies in the same class.